Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer

Journal of Surgical Research

Volumn 143, Issue 1, 2007, Pages 169-176

  Vegeler, Reid C ^a   Yip Schneider, Michele T ^a,b   Ralstin, Matthew ^a   Wu, Huangbing ^a   Crooks, Peter A ^d   Neelakantan, Sundar ^d   Nakshatri, Harikrishna ^a,b   Sweeney, Christopher J ^a,b   Schmidt, C Max ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d University of Kentucky   (United States)

Author keywords

celecoxib; cyclooxygenase (COX); lung cancer; nuclear factor kappa B (NF B); parthenolide

Indexed keywords

AMINE; CELECOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; LC 1; N NITRO BIS(2 OXOPROPYL)AMINE; PARTHENOLIDE; PLACEBO; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LUNG CANCER; LUNG INJURY; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; CARCINOGENS; CRICETINAE; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LUNG; LUNG NEOPLASMS; MESOCRICETUS; NF-KAPPA B; NITROSAMINES; PYRAZOLES; RANDOM ALLOCATION; SESQUITERPENES; SULFONAMIDES;

EID: 35248885740     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.08.007     Document Type: Article

References (54)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10
3. Wahbah M., Boroumand N., Castro C., et al. Changing trends in the distribution of the histologic types of lung cancer: A review of 4439 cases. Ann Diagnost Pathol 11 (2007) 89
4. Carney D.N. Lung cancer-time to move on from chemotherapy. N Engl J Med 346 (2002) 126
5. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346 (2002) 92
6. Bauer A.K., Dwyer-Nield L.D., et al. Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: A role in tumor promotion. Exp Lung Res 27 (2001) 197
7. Dwyer-Nield L.D., Srebernak M.C., Barrett B.S., et al. Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis 26 (2005) 1196
8. Malkinson A., Radcliffe R., Bauer A., et al. Quantitative trait loci that regulate susceptibility to both butylated hydroxytoluene-induced pulmonary inflammation and lung tumor promotion in CXB recombinant inbred mice. Chest 121 (2002) 82S
9. Cohen B.H., Diamond E.L., Graves C.G., et al. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 2 (1977) 523
10. Brown J.R., and DuBois R.N. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10 (2004) 4266s
11. Karin M., and Greten F.R. NF-κB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 (2005) 749
12. Garg A., and Aggarwal B.B. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 16 (2002) 1053
13. Feng L., Sun W., Xia Y., et al. Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression. Arch Biochem Biophys 307 (1993) 361
14. Williams C.S., and DuBois R.N. Prostaglandin endoperoxide synthase: Why two isoforms?. Am J Physiol 270 (1996) G393
15. Furukawa F., Nishikawa A., Lee I.S., et al. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int J Cancer 104 (2003) 269
16. Takahashi T., Kozaki K., Yatabe Y., et al. Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol 21 (2002) 177
17. Chun K.S., and Surh Y.J. Signal transduction pathways regulating cyclooxygenase-2 expression: Potential molecular targets for chemoprevention. Biochem Pharmacol 68 (2004) 1089
18. Sweeney C.J., Marshall M.S., Barnard D.S., et al. Cyclooxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev 26 (2002) 238
19. Yip-Schneider M.T., Barnard D.S., Billings S.D., et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21 (2000) 139
20. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37 (2000) 431
21. Lin M.T., Lee R.C., Yang P.C., et al. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 276 (2001) 48997
22. Hida T., Kozaki K., Muramatsu H., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6 (2000) 2006
23. Rioux N., and Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 58 (1998) 5354
24. Pommier Y., Sordet O., Antony S., et al. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 23 (2004) 2934
25. Van Antwerp D.J., Martin S.J., Kafri T., et al. Suppression of TNF-alpha-induced apoptosis by NF-κB. Science 274 (1996) 787
26. Wang C.Y., Cusack Jr. J.C., Liu R., et al. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5 (1999) 412
27. Tang X., Liu D., Shishodia S., et al. Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107 (2006) 2637
28. Zhang Z., Ma J., Li N., et al. Expression of nuclear factor-κB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg 82 (2006) 243
29. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946
30. Yip-Schneider M.T., Nakshatri H., Sweeney C.J., et al. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κ B pathway in pancreatic carcinoma cells. Mol Cancer Ther 4 (2005) 587
31. Pour P., Althoff J., Kruger F.W., et al. A potent pancreatic carcinogen in Syrian hamsters: N-nitrosobis(2-oxopropyl)amine. J Natl Cancer Inst 58 (1977) 1449
32. Furukawa F., Nishikawa A., Imazawa T., et al. Enhancing effects of quinacrine on development of hepatopancreatic lesions in N-nitrosobis(2-oxopropyl)amine-initiated hamsters. Jpn J Cancer Res 89 (1998) 131
33. Son H.Y., Nishikawa A., Furukawa F., et al. Modifying effects of 4-phenylbutyl isothiocyanate on N-nitrosobis(2-oxopropyl)amine-induced tumorigenesis in hamsters. Cancer Lett 160 (2000) 141
34. Yip-Schneider M.T., Wu H., Ralstin M., et al. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther 6 (2007) 1736
35. Soslow R.A., Dannenberg A.J., Rush D., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637
36. Colby T.V., Wistuba I.I., and Gazdar A. Precursors to pulmonary neoplasia. Adv Anat Pathol 5 (1998) 205
37. Mao J.T., Fishbein M.C., Adams B., et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 12 (2006) 314
38. Kisley L.R., Barrett B.S., Dwyer-Nield L.D., et al. Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 23 (2002) 1653
39. Diperna C.A., Bart R.D., Sievers E.M., et al. Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg 126 (2003) 1129
40. Dannenberg A.J., and DuBois R.N. COX-2: A new target for cancer prevention and treatment (2003), Karger, Basel and New York 159
41. Denlinger C.E., Rundall B.K., and Jones D.R. Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: The role of NF-κB. Semin Thorac Cardiovasc Surg 16 (2004) 28
42. Tichelaar J.W., Zhang Y., leRiche J.C., et al. Increased staining for phospho-Akt, p65/RELA and cIAP-2 in preneoplastic human bronchial biopsies. BMC Cancer 5 (2005) 155
43. Singh R.P., Mallikarjuna G.U., Sharma G., et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor κB-mediated inducible chemoresistance. Clin Cancer Res 10 (2004) 8641
44. Sweeney C.J., Mehrotra S., Sadaria M.R., et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 4 (2005) 1004
45. Lou Y., Vitalis T.Z., Basha G., et al. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res 65 (2005) 7926
46. Nemunaitis J., Dillman R.O., Schwarzenberger P.O., et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24 (2006) 4721
47. Huang M., Sharma S., Mao J.T., et al. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157 (1996) 5512
48. Izumi M., Nakanishi Y., Yoshino I., et al. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 92 (2001) 446
49. Aoe K., Hiraki A., Yamazaki K., et al. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients. Int J Oncol 29 (2006) 65
50. Huang M., Stolina M., Sharma S., et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58 (1998) 1208
51. Stolina M., Sharma S., Lin Y., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164 (2000) 361
52. Neuner A., Schindel M., Wildenberg U., et al. Cytokine secretion: Clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer 34 34 Suppl 2 (2001) S79
53. Alleva D.G., Burger C.J., and Elgert K.D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production. Role of tumor-derived IL-10, TGF-β, and prostaglandin E2. J Immunol 153 (1994) 1674
54. Caputi M., Russo G., Esposito V., et al. Role of cell-cycle regulators in lung cancer. J Cell Physiol 205 (2005) 319